Arlington closes $1.45bn sale of Riverpoint Medical to Novanta
Medical components manufacturer Novanta has closed its $1.45 billion acquisition of Riverpoint Medical, a developer of advanced surgical products, from Arlington Capital Partners.
Novanta, a medical components manufacturer, has finalized the acquisition of Riverpoint Medical from Arlington Capital Partners. Riverpoint Medical is a developer of advanced surgical products. The transaction was first reported by PE Hub. This acquisition underscores continued activity in the medical technology sector. It also highlights the strategic exits private equity firms seek for their portfolio companies. The deal, announced in June, reflects Arlington Capital Partners' strategy in the healthcare market, particularly concerning specialized medical device manufacturing. Novanta paid $1.2 billion in cash upfront for Riverpoint Medical. An additional milestone payment of $250 million is scheduled for the first quarter of 2027. This structure potentially ties a portion of the payment to future performance or specific achievements of Riverpoint Medical. Riverpoint Medical, based in Portland, Oregon, specializes in the development and manufacturing of surgical threads and other surgical consumables. These materials are fiber-based, polymer, and bioabsorbable, and are used in minimally invasive procedures such as sports injury repair, trauma, and heart surgery. The company operates by selling its products to original equipment manufacturers (OEMs), who then rebrand and sell them. Riverpoint Medical also manages the 510(k) clearance process for its products. This service helps OEMs reduce the time and cost associated with bringing new products to market, offering a competitive advantage. The acquisition of Riverpoint Medical by Novanta indicates continued consolidation within the medical device and surgical consumables industry. It shows that companies with specialized manufacturing capabilities and regulatory expertise are attractive targets. This trend suggests a focus on innovative materials and processes that support minimally invasive procedures, driven by demand from large OEMs seeking to streamline their product development and regulatory pathways.